A star of the London HealthTech ecosystem, Huma's remote patient monitoring platform and data/analytics backbone has been approved as a FDA Software-as-a-medical-device (SaMD) Class II offering, as well as receving the EU's MDA Class IIb approval. These details are incredibly important - without these approvals, Huma's platform would ony able to provide data to inform clinical decision making, but having these approvals allows Huma to apply artificial intelligence (AI) algorithms to support clinical decision making, not just provide data. Because of this, Huma is truly both a data and an AI company - and one to keep an eye on, although they don't seem to be hiring at the moment, which could be worrisome. (September 2023)